COMP <GO>
BMRN vs LLY // REVENUE GROWTH (YOY)
BioMarin Pharmaceutical Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: BMRN 4
— LLY 11
▲ REVENUE GROWTH (YOY) LEADER: LLY
LAST: $58.51 (+1.77%) • MKT CAP: $11.13B
revenue-growth
12.90%
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
revenue-growth
45.51%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BMRN VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BMRN | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 77.70% | 83.64% | -5.94 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.00% | 32.36% | -26.36 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.0x | 36.4x | -15.42 | BMRN | /valuation <GO> |
| Free Cash Flow Yield | 6.51% | 2.30% | +4.21 | BMRN | /fcf-yield <GO> |
| Operating Margin | 12.70% | 40.21% | -27.51 | LLY | /operating-margins <GO> |
| Net Profit Margin | 10.80% | 31.90% | -21.10 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 12.90% | 45.51% | -32.61 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.57 | 9.29 | -3.72 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 6.77% | -0.07 | BMRN | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.5 | 77.9 | -23.36 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 0.51 | +0.44 | BMRN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.8x | 26.3x | +0.55 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.13B | $1.33T | -$1.32T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BMRN REV | LLY REV | BMRN GROSS % | LLY GROSS % | BMRN FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.22B | $65.18B | 77.7% | 83.0% | $725.0M | $16.81B |
| FY 2024 | $2.85B | $45.04B | 79.7% | 81.3% | $487.4M | $8.82B |
| FY 2023 | $2.42B | $34.12B | 44.0% | 79.3% | $50.4M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BMRN // BETA 0.95
LLY // BETA 0.51